-
Something wrong with this record ?
Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP
M Ceckova, Z Vackova, H Radilova, A Libra, M Buncek, F Staud
Language English Country Great Britain
Document type Research Support, Non-U.S. Gov't
Grant support
1A8696
MZ0
CEP Register
- MeSH
- ATP-Binding Cassette Transporters metabolism MeSH
- Apoptosis drug effects MeSH
- Models, Biological MeSH
- Drug Resistance, Neoplasm MeSH
- Cisplatin administration & dosage pharmacology toxicity MeSH
- Inhibitory Concentration 50 MeSH
- Carboplatin administration & dosage pharmacology toxicity MeSH
- Cells, Cultured MeSH
- Humans MeSH
- Neoplasm Proteins metabolism MeSH
- Organoplatinum Compounds administration & dosage pharmacology toxicity MeSH
- Antineoplastic Agents administration & dosage pharmacology toxicity MeSH
- Dogs MeSH
- Drug Screening Assays, Antitumor methods MeSH
- Transfection methods MeSH
- Green Fluorescent Proteins pharmacology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Dogs MeSH
- Animals MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
ATP-binding drug efflux transporters decrease intracellular concentrations of cytotoxic drugs, causing multidrug resistance in cancer. In this study, we examined possible interactions of ABCG2 transporter with platinum cytotoxic drugs. We demonstrate here an interference of platinum drugs with enhanced green fluorescence protein (EGFP) in the cellular models, where EGFP was employed as a reporter gene. Cytotoxicity of cisplatin (CIP), carboplatin (CAP) and oxaliplatin (OXP) was significantly lowered in MDCKII cells transfected with ABCG2 transporter and EGFP reporter. The IC(50) values in MDCKII-ABCG2 were 25.7, 164 and 165 microM for CIP, CAP and OXP, respectively, whereas IC(50) for the same cytostatics in MDCKII cells were as follows: 15.4, 133 and 50.3 microM. Addition of fumitremorgin C (FTC), a potent ABCG2 inhibitor, significantly suppressed the resistance of MDCKII-ABCG2 to OXP, suggesting that OXP interacts with ABCG2. However, FTC did not change the sensitivity of the cells to CIP and CAP. We assume that EGFP rather than ABCG2 causes the diminished toxicity of the platinum cytostatics in the transfected cells. This hypothesis was confirmed in human Hep2 cells expressing EGFP: using MTT test, IC(50) of 30.0, 247 and 27.9 microM were obtained for CIP, CAP and OXP, respectively, while 12.3, 106 and 20.5 microM were observed in the parent Hep2 cells. Employing neutral red cytotoxicity assay, similar data were obtained (IC(50) 7.73, 685 and 112 microM for CIP, CAP, and OXP, respectively, in the Hep2-EGFP cells and 1.65, 79.4 and 24.5 microM in the parent Hep2 cells). Caspase-3/7 assay revealed lower susceptibility of EGFP expressing Hep2 cells to apoptosis induced by CIP when compared to the parent cell line. We therefore conclude that EGFP in transfected cells interferes with cytotoxicity of platinum drugs by hindering the drug induced apoptosis and could cause misinterpretation of results obtained in cytotoxicity studies.
- 000
- 04217naa 2200565 a 4500
- 001
- bmc11006306
- 003
- CZ-PrNML
- 005
- 20140228114828.0
- 008
- 110401s2008 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Čečková, Martina $7 xx0049092
- 245 10
- $a Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP / $c M Ceckova, Z Vackova, H Radilova, A Libra, M Buncek, F Staud
- 314 __
- $a Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.
- 520 9_
- $a ATP-binding drug efflux transporters decrease intracellular concentrations of cytotoxic drugs, causing multidrug resistance in cancer. In this study, we examined possible interactions of ABCG2 transporter with platinum cytotoxic drugs. We demonstrate here an interference of platinum drugs with enhanced green fluorescence protein (EGFP) in the cellular models, where EGFP was employed as a reporter gene. Cytotoxicity of cisplatin (CIP), carboplatin (CAP) and oxaliplatin (OXP) was significantly lowered in MDCKII cells transfected with ABCG2 transporter and EGFP reporter. The IC(50) values in MDCKII-ABCG2 were 25.7, 164 and 165 microM for CIP, CAP and OXP, respectively, whereas IC(50) for the same cytostatics in MDCKII cells were as follows: 15.4, 133 and 50.3 microM. Addition of fumitremorgin C (FTC), a potent ABCG2 inhibitor, significantly suppressed the resistance of MDCKII-ABCG2 to OXP, suggesting that OXP interacts with ABCG2. However, FTC did not change the sensitivity of the cells to CIP and CAP. We assume that EGFP rather than ABCG2 causes the diminished toxicity of the platinum cytostatics in the transfected cells. This hypothesis was confirmed in human Hep2 cells expressing EGFP: using MTT test, IC(50) of 30.0, 247 and 27.9 microM were obtained for CIP, CAP and OXP, respectively, while 12.3, 106 and 20.5 microM were observed in the parent Hep2 cells. Employing neutral red cytotoxicity assay, similar data were obtained (IC(50) 7.73, 685 and 112 microM for CIP, CAP, and OXP, respectively, in the Hep2-EGFP cells and 1.65, 79.4 and 24.5 microM in the parent Hep2 cells). Caspase-3/7 assay revealed lower susceptibility of EGFP expressing Hep2 cells to apoptosis induced by CIP when compared to the parent cell line. We therefore conclude that EGFP in transfected cells interferes with cytotoxicity of platinum drugs by hindering the drug induced apoptosis and could cause misinterpretation of results obtained in cytotoxicity studies.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a ABC transportéry $x metabolismus $7 D018528
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x farmakologie $x toxicita $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a karboplatina $x aplikace a dávkování $x farmakologie $x toxicita $7 D016190
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a cisplatina $x aplikace a dávkování $x farmakologie $x toxicita $7 D002945
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a screeningové testy protinádorových léčiv $x metody $7 D004354
- 650 _2
- $a zelené fluorescenční proteiny $x farmakologie $7 D049452
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a organoplatinové sloučeniny $x aplikace a dávkování $x farmakologie $x toxicita $7 D009944
- 650 _2
- $a transfekce $x metody $7 D014162
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vacková, Zuzana $7 xx0126212
- 700 1_
- $a Radilová, Hana $7 mzk2006348915
- 700 1#
- $a Libra, Antonín. $7 _BN007788
- 700 1_
- $a Bunček, Martin, $d 1975- $7 mzk2006348916
- 700 1_
- $a Štaud, František, $d 1970- $7 stk2007393932
- 773 0_
- $t Toxicology in Vitro $w MED00004536 $g Roč. 22, č. 8 (2008), s. 1846-1852 $x 0887-2333
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110414103904 $b ABA008
- 991 __
- $a 20140228115642 $b ABA008
- 999 __
- $a ok $b bmc $g 833908 $s 698402
- BAS __
- $a 3
- BMC __
- $a 2008 $b 22 $c 8 $x MED00004536 $d 1846-1852 $i 0887-2333 $m Toxicology in vitro $n Toxicol In Vitro
- GRA __
- $a 1A8696 $p MZ0
- LZP __
- $a 2011-1B09/jjme